SlideShare une entreprise Scribd logo
1  sur  31
TOKSIKOLOGI OBATTOKSIKOLOGI OBAT
OBAT YG SERINGOBAT YG SERING
MENYEBABKAN KERACUNANMENYEBABKAN KERACUNAN
 ANTIHISTAMINANTIHISTAMIN
 ANALGETIKAANALGETIKA
 VITAMIN, MINERALVITAMIN, MINERAL
 OBAT FLUOBAT FLU
 HORMONHORMON
 ANTIBIOTIK INTERNALANTIBIOTIK INTERNAL
NONO KRITERIA TOKSIKKRITERIA TOKSIK DOSISDOSIS
11 PRAKTIS NON TOKSIKPRAKTIS NON TOKSIK > 15 G/KG BB> 15 G/KG BB
22 SEDIKIT TOKSIKSEDIKIT TOKSIK 5 – 15 G/KG BB5 – 15 G/KG BB
33 TOKSISITAS SEDANGTOKSISITAS SEDANG 0,5 – 5 G/KG BB0,5 – 5 G/KG BB
44 SANGAT TOKSIKSANGAT TOKSIK 50-500 MG/KG BB50-500 MG/KG BB
55 TOKSIK EKSTREMTOKSIK EKSTREM 5-50 MG/KG BB5-50 MG/KG BB
66 SUPER TOKSIKSUPER TOKSIK < 5 MG/KG BB< 5 MG/KG BB
INDEKS TERAPIINDEKS TERAPI = LD 50 / ED 50= LD 50 / ED 50
MAKINMAKIN BESARBESAR MAKINMAKIN AMANAMAN
URUTAN TOKSISITAS DITINJAU DARIURUTAN TOKSISITAS DITINJAU DARI
RUTE PEMBERIAN:RUTE PEMBERIAN:
IV > INHALASI > IP > SC > IM > INTRAIV > INHALASI > IP > SC > IM > INTRA
DERMAL > ORAL > TOPIKALDERMAL > ORAL > TOPIKAL
EFEKEFEK
TOKSISITASTOKSISITAS
OBATOBAT
EMESISEMESIS SALISILATSALISILAT
KONSTIPASIKONSTIPASI NARKOTIKANARKOTIKA
BRADICARDIBRADICARDI NARKOTIKA, SEDATIVENARKOTIKA, SEDATIVE
TACHICARDITACHICARDI AMFETAMIN, ATROPIN,AMFETAMIN, ATROPIN,
SALISILAT, KOKAINSALISILAT, KOKAIN
MULUT KERINGMULUT KERING AMFETAMIN, ATROPIN,AMFETAMIN, ATROPIN,
ANTIHISTAMIN,ANTIHISTAMIN,
NARKOTIKNARKOTIK
ATAKSIAATAKSIA BARBITURAT, FENITOIN,BARBITURAT, FENITOIN,
HALUSINOGENHALUSINOGEN
KOMA, DEPRESIKOMA, DEPRESI A.HISTAMIN, A.PSIKOTIKA.HISTAMIN, A.PSIKOTIK
PENANGANAN KERACUNANPENANGANAN KERACUNAN
PENILAIANPENILAIAN
 FUNGSI RESPIRASIFUNGSI RESPIRASI
 FUNGSI KARDIOVASKULARFUNGSI KARDIOVASKULAR
 GEJALA SSPGEJALA SSP
 GEJALA LAINGEJALA LAIN
 PENENTUAN KERACUANANPENENTUAN KERACUANAN
FAKTOR YGFAKTOR YG
MEMPENGARUHIMEMPENGARUHI
TOKSISITASTOKSISITAS
 KOMPOSISIKOMPOSISI
 DOSISDOSIS
 RUTE PEMBERIANRUTE PEMBERIAN
 METABOLISME TOKSIKMETABOLISME TOKSIK
 KONDISI KESEHATANKONDISI KESEHATAN
 USIA KEMATANGANUSIA KEMATANGAN
 KONDISI NUTRISIKONDISI NUTRISI
 GENETIKGENETIK
 KELAMINKELAMIN
 LINGKUNGANLINGKUNGAN
FAKTOR YANG MENENTUKANFAKTOR YANG MENENTUKAN
TOKSISITASTOKSISITAS
LD 50LD 50
EFEK SAMPINGEFEK SAMPING
KECEPATAN TIMBULNYA EFEKKECEPATAN TIMBULNYA EFEK
CARA PENANGANANCARA PENANGANAN
 PENCUCIAN/LAVAGEPENCUCIAN/LAVAGE
 EMESISEMESIS
 ADSORBENTADSORBENT
 KATARTIKKATARTIK
 DEMULSENDEMULSEN
 DEKONTAMINASI TOPIKALDEKONTAMINASI TOPIKAL
 MENINGKATKAN ELIMINASI ZAT TOKSIKMENINGKATKAN ELIMINASI ZAT TOKSIK
 ANTIDOTANTIDOT
PENCUCIANPENCUCIAN
JK RACUN HRS SGR DIKELUATKAN DRJK RACUN HRS SGR DIKELUATKAN DR
LAMBUNGLAMBUNG
INDIKASIINDIKASI
 1010TIDAK SADAR/SETENGAH SADARTIDAK SADAR/SETENGAH SADAR
 REFLEKS MENELAN HILANG:REFLEKS MENELAN HILANG:
S.IPECAC TIDAK BISAS.IPECAC TIDAK BISA
 SANGAT TOKSIK & BANYAKSANGAT TOKSIK & BANYAK
KI :ZAT KOROSIFKI :ZAT KOROSIF
PASIEN KEJANGPASIEN KEJANG
CAIRAN PENCUCIANCAIRAN PENCUCIAN
 NaHCO3NaHCO3
 Larutan Garam CaLarutan Garam Ca
 Larutan As.TanatLarutan As.Tanat
 KMNO4KMNO4
 NaCl FisiologisNaCl Fisiologis
 AirAir
EMESISEMESIS
JK RACUN MASIH DI SAL CERNAJK RACUN MASIH DI SAL CERNA
SIRUP IPECACSIRUP IPECAC
APOMORFINAPOMORFIN
ALTERNATIF LAINALTERNATIF LAIN
LARUTAN SABUNLARUTAN SABUN
RANGSANGAN MEKANIKRANGSANGAN MEKANIK
KI:KI: OBAT KONVULSANOBAT KONVULSAN
TDK SADAR/REFLEKS MENELAN –TDK SADAR/REFLEKS MENELAN –
PENYAKIT CARDIOVASKULARPENYAKIT CARDIOVASKULAR
EMPISEMAEMPISEMA
ADSORBENADSORBEN
JK RACUN DPT DIABS D/ ABSORBENJK RACUN DPT DIABS D/ ABSORBEN
 KARBON AKTIFKARBON AKTIF
 KAOLINKAOLIN
 PEKTINPEKTIN
 ATALPUGITATALPUGIT
 KOLESTIRAMINKOLESTIRAMIN
ABSORBSI < :TOLBUTAMID, ZAT TDKABSORBSI < :TOLBUTAMID, ZAT TDK
LRT AIRLRT AIR
KATARTIK
JK DIDUGA ZAT TOKSIK SDH MSK USUS
 MgSO4
 Mg SITRAT
 Na SULFAT
 Na FOSFAT
 SORBITOL
 Sbg pencahar
DEMULSEN
• ES KRIM
• SUSU
• PUTIH TELUR
 Lapisi muk zat
racun yg korosif
DEKONTAMINASI
TOPIKAL
• AIR
• SABUN
 u/ zat iritan
PENINGKATAN ELIMINASIPENINGKATAN ELIMINASI
 DIURETIK KUATDIURETIK KUAT
 Yg dpt dikeluarkan diuretik kuatYg dpt dikeluarkan diuretik kuat
amfetamin,penicillin,salisilat,sulfonamidaamfetamin,penicillin,salisilat,sulfonamida
KI : ACETAMINOPHEN,FENOTIAZINKI : ACETAMINOPHEN,FENOTIAZIN
A.DEPRESSAN TRISIKLIK,barbiturat krjA.DEPRESSAN TRISIKLIK,barbiturat krj
pendekpendek
**DIALISISDIALISIS
*PENGASAMAN/PEMBASAAN URIN*PENGASAMAN/PEMBASAAN URIN
ANTIDOTANTIDOT
 KIMIAKIMIA
 RESEPTORRESEPTOR
 DISPOSIONALDISPOSIONAL
 FUNGSIONAL/FISIOLOGISFUNGSIONAL/FISIOLOGIS
 ANTIDOTANTIDOT
ATROPIN----------------ATROPIN----------------
DIAZEPAM--------------DIAZEPAM--------------
DEKTROSE-------------DEKTROSE-------------
ADRENALIN------------ADRENALIN------------
DOPAMIN---------------DOPAMIN---------------
NALOKSON-------------NALOKSON-------------
NITROPRUSID---------NITROPRUSID---------
--
PROTAMIN SULFAT--PROTAMIN SULFAT--
VIT K-----------------VIT K-----------------
ASETILASETIL
SISTEIN-----SISTEIN-----
 RACUN/GEJALARACUN/GEJALA
KOLINESTERASE INHKOLINESTERASE INH
STIMULAN SSPSTIMULAN SSP
HIPOGLIKEMIKHIPOGLIKEMIK
ANAPHYLAKSIISANAPHYLAKSIIS
HIPOTENSIHIPOTENSI
OPIOIDOPIOID
HIPERTENSIHIPERTENSI
HEPARINHEPARIN
ANTIKOAGULANORALANTIKOAGULANORAL
ACHETAMINOPHENACHETAMINOPHEN
KERACUNAN ACETAMINOPHEN
 MK: METABOLIT REAKTIF IK SEL
NECROSIS
HB MET HB(TDK IK O2)
O2
PAR
HB
(ENZ MET HB REDUKTASE)
KOFAKTOR : GLUTATION
• AnjAnj  nekrosis hepatiknekrosis hepatik
• KucKuc Met HemoglobinemiaMet Hemoglobinemia
DOSIS TOKSIKDOSIS TOKSIK
ANJ : 150 MG/KGANJ : 150 MG/KG
KUC : 50 MG/KGKUC : 50 MG/KG
(DOSIS AN: 80 MG(DOSIS AN: 80 MG
REG: 325-500MG)REG: 325-500MG)
GEJALAGEJALA
► ANJ: - DEPRESIANJ: - DEPRESI
- MUNTAH- MUNTAH
- SKT ABD- SKT ABD
- URIN,SERUM: GELAP- URIN,SERUM: GELAP
- MATI ( 2-5 HR)- MATI ( 2-5 HR)
► KUCKUC
- ANOREKSI,SALIVASI,VOMIT- ANOREKSI,SALIVASI,VOMIT
- DEPRESI- DEPRESI
- METHBNEMIA, HEMOGLOBINURIA- METHBNEMIA, HEMOGLOBINURIA
- MEMBRAN CYANOTIK- MEMBRAN CYANOTIK
- URIN, DARAH GELAP- URIN, DARAH GELAP
- WAJAH EDEMA- WAJAH EDEMA
- MATI 18-36 J- MATI 18-36 J
 PROGNOSIS: JELEKPROGNOSIS: JELEK
 TREATMENTTREATMENT
- <4J: EMESIS, GASTRIC LAVAGE,- <4J: EMESIS, GASTRIC LAVAGE,
ACTIVATED CHARCOALACTIVATED CHARCOAL
KUC: YOHIMBINKUC: YOHIMBIN
ANJ: APOMORPHINANJ: APOMORPHIN
-GROUP SULFHYDRYL:N--GROUP SULFHYDRYL:N-
ACETILCYSTEINE 140 MG/KGACETILCYSTEINE 140 MG/KG
- VIT C- VIT C
- SUPPORTIVE THERAPY- SUPPORTIVE THERAPY
-INFUSE : DECTROSE 2,5%-INFUSE : DECTROSE 2,5%
-OXYGEN:-OXYGEN:
-TRANSFUSI DRH-TRANSFUSI DRH
ASPIRIN TOXICOSISASPIRIN TOXICOSIS
 KUC > SERING DRPD ANJKUC > SERING DRPD ANJ
C/ KUC:DEF/AKTC/ KUC:DEF/AKT GLUCORONYLGLUCORONYL
TRANSFERASETRANSFERASE <<
(GT : DETOX & EKS ASPIRIN)(GT : DETOX & EKS ASPIRIN)
EFEK TOKSIK:EFEK TOKSIK:
- TEKAN SUTUL- TEKAN SUTUL
- HAMB AGREGASI TROMBOSIT- HAMB AGREGASI TROMBOSIT
- METABOLIC ACIDOSIS- METABOLIC ACIDOSIS
- RENAL DISEASE- RENAL DISEASE
- GASTRIC ULCERASI- GASTRIC ULCERASI
DOSIS TOXIC:DOSIS TOXIC:
- ANJ : 30 MG /KG/HR- ANJ : 30 MG /KG/HR
- KUC : 25 MG/KG/HR- KUC : 25 MG/KG/HR
(ANAK : 81 MG(ANAK : 81 MG
REG : 325- 500 MG)REG : 325- 500 MG)
GJL:-AKUT:GJL:-AKUT:
DEPRESI, ANOREKSI,DEPRESI, ANOREKSI,
HIPERPIREXIA, VOMIT,HIPERPIREXIA, VOMIT,
ATAKSIA,ATAKSIA,
COMA, MATICOMA, MATI
 KRONIK:KRONIK:
GASTRIK ULCER, PERFORASI,GASTRIK ULCER, PERFORASI,
HEPATOTIKSIK, SUPRESI SUTULHEPATOTIKSIK, SUPRESI SUTUL
TREATMENTTREATMENT
1. 6-12 J : EMETIK,GASTREK1. 6-12 J : EMETIK,GASTREK
LAVAGE,LAVAGE,
ACT CHARCOAL, SALINEACT CHARCOAL, SALINE
CATARTIKCATARTIK
2. DIURESIS : DIURETIK KUAT2. DIURESIS : DIURETIK KUAT
IBUPROFENIBUPROFEN
 NSAID YG TDK DIREKOMENDASI UTKNSAID YG TDK DIREKOMENDASI UTK
PETSPETS  IT SEMPITIT SEMPIT
 TOKSISITAS:TOKSISITAS:
- 150 mg/kg- 150 mg/kg vomit, gastric ulcervomit, gastric ulcer
- 300 mg/kg- 300 mg/kg  ggl ginjalggl ginjal
 PROG : JLKPROG : JLK
 TREAT: 1. EMETIK, GASTRIK L, ATREAT: 1. EMETIK, GASTRIK L, A
CHARCOALCHARCOAL
2. support: infus, diuresis2. support: infus, diuresis
3. simpt: sucralfat, ranitidin,3. simpt: sucralfat, ranitidin,
misotrostolmisotrostol g.ulcerg.ulcer
ANTICOAGULANT
 MK : -INH ENZ PD SINTESIS VIT K
- INH FACT COAG PROD VIT K
 TOXIC DOSE
* ANJ : 5-300 MG/KG
(1-5 MG/KG/HR 5-15 HR)
* KUC: 5-30 MG/KG
(1 MG/KG/HR 5 HR)
 GJL:- DEPRESI,LEMAH
- HEMATEMESIS,HEMATURIA,HEMORRHAGE
- MATI HEMORRHAGE D/PLEURAL CAVITY
 DX:-HISTORY
- SCREENING KOAG: BLEEDING TIME, COAG TIME
- ANALISIS A.COAG KIMIA
• TREATMENT
1. INDUKSI EMESIS, GASTRIC LAVAGE, ACTIVED
CHATCOAL, CATHARTIC
2. ANTIDOTE: VIT K
3. TREAT CLINICAL SIGN
- INTRAPULMONARY HEMORRHAGE:
TRANSFUSI PLASMA, O2, TDK BOLEH
DIBERI FUROSEMIDE INH FS PLATELET
- HIPOVOLEMIC SHOCK: INFUSE,TRANSF
DRH, KORTICOSTEROID,
A.HISTAMIN&DECONGESTAN
 DX: SEJARAH PSEUDOEPHEDRIN,
(PHENYLPROPANOLAMINE)/PPA,DIPHENH
YDRAMINE, CHLORPHENIRAMINE
 GJL:- DEPRESI, GG RESP,
- HIPEREXCITABILITY
- TREMOR, SEIZURES, HIPERACTIVITY
- VOMIT, MIDRIASIS, HIPERTERMIA
- DISORIENTASI
- BRADICARD/TACHICARD
 PROG: BAIK
 TREAT:
1. < 1 J INTAKEEMESIS
2. ACTIVATED CHARCOAL
3. SUPPORTIVE: INFUSE, O2
4. OBAT SEDATIVE HIPERACVTIVE
(DIAZEPAM,PHENOBARBITAL)
5. PROPANOLOLTACHYCARDI
6. ATROPINE BRADYCARD

Contenu connexe

Tendances

Tendances (20)

Komunikasi dalam farmasi
Komunikasi dalam farmasi Komunikasi dalam farmasi
Komunikasi dalam farmasi
 
Efek samping obat
Efek samping obat Efek samping obat
Efek samping obat
 
penggolongan obat menurut pemerintah
 penggolongan obat menurut pemerintah penggolongan obat menurut pemerintah
penggolongan obat menurut pemerintah
 
Pedoman farmakoekonomi
Pedoman farmakoekonomiPedoman farmakoekonomi
Pedoman farmakoekonomi
 
SWAMEDIKASI
SWAMEDIKASISWAMEDIKASI
SWAMEDIKASI
 
Dosis obat (3)
Dosis obat (3)Dosis obat (3)
Dosis obat (3)
 
Kasus farmakoterapi I
Kasus farmakoterapi IKasus farmakoterapi I
Kasus farmakoterapi I
 
Analisis resep
Analisis resepAnalisis resep
Analisis resep
 
Toksikologi 2017
Toksikologi 2017Toksikologi 2017
Toksikologi 2017
 
Metode soap
Metode soapMetode soap
Metode soap
 
Jenis, Indikasi, Dosis, dan Efek Samping Obat
Jenis, Indikasi, Dosis, dan Efek Samping ObatJenis, Indikasi, Dosis, dan Efek Samping Obat
Jenis, Indikasi, Dosis, dan Efek Samping Obat
 
Farmakologi
Farmakologi Farmakologi
Farmakologi
 
Farmakologi (Prinsip-Prinsip Terapeutika, Keamanan, dan Efikasi Pengobatan)
Farmakologi  (Prinsip-Prinsip Terapeutika, Keamanan, dan Efikasi Pengobatan)Farmakologi  (Prinsip-Prinsip Terapeutika, Keamanan, dan Efikasi Pengobatan)
Farmakologi (Prinsip-Prinsip Terapeutika, Keamanan, dan Efikasi Pengobatan)
 
Biofarmasetika (Pendahuluan)
Biofarmasetika (Pendahuluan)Biofarmasetika (Pendahuluan)
Biofarmasetika (Pendahuluan)
 
Kelompok 12(1)
Kelompok 12(1)Kelompok 12(1)
Kelompok 12(1)
 
Farmakologi cara pemberian obat
Farmakologi cara pemberian obatFarmakologi cara pemberian obat
Farmakologi cara pemberian obat
 
77599001 dosis-obat
77599001 dosis-obat77599001 dosis-obat
77599001 dosis-obat
 
Interaksi obat & reseptor
Interaksi obat & reseptorInteraksi obat & reseptor
Interaksi obat & reseptor
 
Diare
DiareDiare
Diare
 
Konsep Dasar Farmakosetik, Farmakokinetik
Konsep Dasar Farmakosetik, FarmakokinetikKonsep Dasar Farmakosetik, Farmakokinetik
Konsep Dasar Farmakosetik, Farmakokinetik
 

Similaire à TOKSIKOLOGI OBAT

Pituitary gland disorders and anesthetic management
Pituitary gland disorders and anesthetic managementPituitary gland disorders and anesthetic management
Pituitary gland disorders and anesthetic managementUnnikrishnan Prathapadas
 
5. pharma musculoskeletal system
5. pharma musculoskeletal system5. pharma musculoskeletal system
5. pharma musculoskeletal systemjhonee balmeo
 
Newer drugs in management of glaucoma
Newer drugs in management of glaucomaNewer drugs in management of glaucoma
Newer drugs in management of glaucomaDrArvindMorya
 
COPD COMPLETE POWER POINT AS PER GOLD....
COPD COMPLETE POWER POINT AS PER GOLD....COPD COMPLETE POWER POINT AS PER GOLD....
COPD COMPLETE POWER POINT AS PER GOLD....V467
 
Disease modifying anti rheumatoid drugs in rheumatoid arhtritis
Disease modifying anti rheumatoid drugs in rheumatoid arhtritisDisease modifying anti rheumatoid drugs in rheumatoid arhtritis
Disease modifying anti rheumatoid drugs in rheumatoid arhtritisBipulBorthakur
 
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda Jain
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda JainOBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda Jain
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda JainLifecare Centre
 
Osteoporosis treatment & surgical significance
Osteoporosis  treatment & surgical significanceOsteoporosis  treatment & surgical significance
Osteoporosis treatment & surgical significanceVinoth Kumar
 
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptx
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptxDIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptx
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptxsubhayan999
 
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdfBASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdfnajmishafiz
 
Respiratory illness treatment
Respiratory illness treatmentRespiratory illness treatment
Respiratory illness treatmentKamal Sharma
 
HYPERGLYCEMIA ppt puskesmas anamnesis ttx
HYPERGLYCEMIA ppt puskesmas anamnesis ttxHYPERGLYCEMIA ppt puskesmas anamnesis ttx
HYPERGLYCEMIA ppt puskesmas anamnesis ttxtiti224002
 
1362566341 surgical treatment of diabetic foot
1362566341 surgical treatment of diabetic foot1362566341 surgical treatment of diabetic foot
1362566341 surgical treatment of diabetic footdfsimedia
 
Corticosteroids in dentistry - DIVYA SINGH.pptx
Corticosteroids in dentistry - DIVYA SINGH.pptxCorticosteroids in dentistry - DIVYA SINGH.pptx
Corticosteroids in dentistry - DIVYA SINGH.pptxSiddharthSingh639
 
Factors affecting drug action pdf
Factors affecting drug action pdfFactors affecting drug action pdf
Factors affecting drug action pdfAarushiSharma54
 
Drugs for neutropenia
Drugs for neutropeniaDrugs for neutropenia
Drugs for neutropeniaDeepak Anand
 
penyakit infeksi pada anak
penyakit infeksi pada anakpenyakit infeksi pada anak
penyakit infeksi pada anakKindal
 

Similaire à TOKSIKOLOGI OBAT (20)

Pituitary gland disorders and anesthetic management
Pituitary gland disorders and anesthetic managementPituitary gland disorders and anesthetic management
Pituitary gland disorders and anesthetic management
 
5. pharma musculoskeletal system
5. pharma musculoskeletal system5. pharma musculoskeletal system
5. pharma musculoskeletal system
 
Steroids ppt
Steroids pptSteroids ppt
Steroids ppt
 
Newer drugs in management of glaucoma
Newer drugs in management of glaucomaNewer drugs in management of glaucoma
Newer drugs in management of glaucoma
 
COPD COMPLETE POWER POINT AS PER GOLD....
COPD COMPLETE POWER POINT AS PER GOLD....COPD COMPLETE POWER POINT AS PER GOLD....
COPD COMPLETE POWER POINT AS PER GOLD....
 
Disease modifying anti rheumatoid drugs in rheumatoid arhtritis
Disease modifying anti rheumatoid drugs in rheumatoid arhtritisDisease modifying anti rheumatoid drugs in rheumatoid arhtritis
Disease modifying anti rheumatoid drugs in rheumatoid arhtritis
 
CASE STUDY GERD
CASE STUDY GERDCASE STUDY GERD
CASE STUDY GERD
 
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda Jain
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda JainOBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda Jain
OBESITY,NUTRITION, METABOLIC SYNDROME update Dr Rahul Jain & Dr Sharda Jain
 
Osteoporosis treatment & surgical significance
Osteoporosis  treatment & surgical significanceOsteoporosis  treatment & surgical significance
Osteoporosis treatment & surgical significance
 
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptx
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptxDIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptx
DIAGNOSTIC APPROACH AND MANAGEMENT OF ACUTE KIDNEY INJURY - Copy.pptx
 
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdfBASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
BASIC ICU & OT NOTES 2021 (VERSION 3) FINAL.pdf
 
Respiratory illness treatment
Respiratory illness treatmentRespiratory illness treatment
Respiratory illness treatment
 
HYPERGLYCEMIA ppt puskesmas anamnesis ttx
HYPERGLYCEMIA ppt puskesmas anamnesis ttxHYPERGLYCEMIA ppt puskesmas anamnesis ttx
HYPERGLYCEMIA ppt puskesmas anamnesis ttx
 
1362566341 surgical treatment of diabetic foot
1362566341 surgical treatment of diabetic foot1362566341 surgical treatment of diabetic foot
1362566341 surgical treatment of diabetic foot
 
Corticosteroids in dentistry - DIVYA SINGH.pptx
Corticosteroids in dentistry - DIVYA SINGH.pptxCorticosteroids in dentistry - DIVYA SINGH.pptx
Corticosteroids in dentistry - DIVYA SINGH.pptx
 
Hemostatika
HemostatikaHemostatika
Hemostatika
 
Factors affecting drug action pdf
Factors affecting drug action pdfFactors affecting drug action pdf
Factors affecting drug action pdf
 
Drugs for neutropenia
Drugs for neutropeniaDrugs for neutropenia
Drugs for neutropenia
 
penyakit infeksi pada anak
penyakit infeksi pada anakpenyakit infeksi pada anak
penyakit infeksi pada anak
 
Dr tarek NSAIDs
Dr tarek NSAIDsDr tarek NSAIDs
Dr tarek NSAIDs
 

Dernier

The Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationThe Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationNathan Young
 
proposal kumeneger edited.docx A kumeeger
proposal kumeneger edited.docx A kumeegerproposal kumeneger edited.docx A kumeeger
proposal kumeneger edited.docx A kumeegerkumenegertelayegrama
 
Quality by design.. ppt for RA (1ST SEM
Quality by design.. ppt for  RA (1ST SEMQuality by design.. ppt for  RA (1ST SEM
Quality by design.. ppt for RA (1ST SEMCharmi13
 
Event 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxEvent 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxaryanv1753
 
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...漢銘 謝
 
Call Girls In Aerocity 🤳 Call Us +919599264170
Call Girls In Aerocity 🤳 Call Us +919599264170Call Girls In Aerocity 🤳 Call Us +919599264170
Call Girls In Aerocity 🤳 Call Us +919599264170Escort Service
 
Engaging Eid Ul Fitr Presentation for Kindergartners.pptx
Engaging Eid Ul Fitr Presentation for Kindergartners.pptxEngaging Eid Ul Fitr Presentation for Kindergartners.pptx
Engaging Eid Ul Fitr Presentation for Kindergartners.pptxAsifArshad8
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRRsarwankumar4524
 
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRachelAnnTenibroAmaz
 
Internship Presentation | PPT | CSE | SE
Internship Presentation | PPT | CSE | SEInternship Presentation | PPT | CSE | SE
Internship Presentation | PPT | CSE | SESaleh Ibne Omar
 
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...Henrik Hanke
 
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comSaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comsaastr
 
General Elections Final Press Noteas per M
General Elections Final Press Noteas per MGeneral Elections Final Press Noteas per M
General Elections Final Press Noteas per MVidyaAdsule1
 
Early Modern Spain. All about this period
Early Modern Spain. All about this periodEarly Modern Spain. All about this period
Early Modern Spain. All about this periodSaraIsabelJimenez
 
Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸mathanramanathan2005
 
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power
 
Application of GIS in Landslide Disaster Response.pptx
Application of GIS in Landslide Disaster Response.pptxApplication of GIS in Landslide Disaster Response.pptx
Application of GIS in Landslide Disaster Response.pptxRoquia Salam
 
Chizaram's Women Tech Makers Deck. .pptx
Chizaram's Women Tech Makers Deck.  .pptxChizaram's Women Tech Makers Deck.  .pptx
Chizaram's Women Tech Makers Deck. .pptxogubuikealex
 

Dernier (18)

The Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism PresentationThe Ten Facts About People With Autism Presentation
The Ten Facts About People With Autism Presentation
 
proposal kumeneger edited.docx A kumeeger
proposal kumeneger edited.docx A kumeegerproposal kumeneger edited.docx A kumeeger
proposal kumeneger edited.docx A kumeeger
 
Quality by design.. ppt for RA (1ST SEM
Quality by design.. ppt for  RA (1ST SEMQuality by design.. ppt for  RA (1ST SEM
Quality by design.. ppt for RA (1ST SEM
 
Event 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptxEvent 4 Introduction to Open Source.pptx
Event 4 Introduction to Open Source.pptx
 
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
THE COUNTRY WHO SOLVED THE WORLD_HOW CHINA LAUNCHED THE CIVILIZATION REVOLUTI...
 
Call Girls In Aerocity 🤳 Call Us +919599264170
Call Girls In Aerocity 🤳 Call Us +919599264170Call Girls In Aerocity 🤳 Call Us +919599264170
Call Girls In Aerocity 🤳 Call Us +919599264170
 
Engaging Eid Ul Fitr Presentation for Kindergartners.pptx
Engaging Eid Ul Fitr Presentation for Kindergartners.pptxEngaging Eid Ul Fitr Presentation for Kindergartners.pptx
Engaging Eid Ul Fitr Presentation for Kindergartners.pptx
 
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRRINDIAN GCP GUIDELINE. for Regulatory  affair 1st sem CRR
INDIAN GCP GUIDELINE. for Regulatory affair 1st sem CRR
 
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATIONRACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
RACHEL-ANN M. TENIBRO PRODUCT RESEARCH PRESENTATION
 
Internship Presentation | PPT | CSE | SE
Internship Presentation | PPT | CSE | SEInternship Presentation | PPT | CSE | SE
Internship Presentation | PPT | CSE | SE
 
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...
DGT @ CTAC 2024 Valencia: Most crucial invest to digitalisation_Sven Zoelle_v...
 
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.comSaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
SaaStr Workshop Wednesday w/ Kyle Norton, Owner.com
 
General Elections Final Press Noteas per M
General Elections Final Press Noteas per MGeneral Elections Final Press Noteas per M
General Elections Final Press Noteas per M
 
Early Modern Spain. All about this period
Early Modern Spain. All about this periodEarly Modern Spain. All about this period
Early Modern Spain. All about this period
 
Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸Mathan flower ppt.pptx slide orchids ✨🌸
Mathan flower ppt.pptx slide orchids ✨🌸
 
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular PlasticsDutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
Dutch Power - 26 maart 2024 - Henk Kras - Circular Plastics
 
Application of GIS in Landslide Disaster Response.pptx
Application of GIS in Landslide Disaster Response.pptxApplication of GIS in Landslide Disaster Response.pptx
Application of GIS in Landslide Disaster Response.pptx
 
Chizaram's Women Tech Makers Deck. .pptx
Chizaram's Women Tech Makers Deck.  .pptxChizaram's Women Tech Makers Deck.  .pptx
Chizaram's Women Tech Makers Deck. .pptx
 

TOKSIKOLOGI OBAT

  • 2. OBAT YG SERINGOBAT YG SERING MENYEBABKAN KERACUNANMENYEBABKAN KERACUNAN  ANTIHISTAMINANTIHISTAMIN  ANALGETIKAANALGETIKA  VITAMIN, MINERALVITAMIN, MINERAL  OBAT FLUOBAT FLU  HORMONHORMON  ANTIBIOTIK INTERNALANTIBIOTIK INTERNAL
  • 3. NONO KRITERIA TOKSIKKRITERIA TOKSIK DOSISDOSIS 11 PRAKTIS NON TOKSIKPRAKTIS NON TOKSIK > 15 G/KG BB> 15 G/KG BB 22 SEDIKIT TOKSIKSEDIKIT TOKSIK 5 – 15 G/KG BB5 – 15 G/KG BB 33 TOKSISITAS SEDANGTOKSISITAS SEDANG 0,5 – 5 G/KG BB0,5 – 5 G/KG BB 44 SANGAT TOKSIKSANGAT TOKSIK 50-500 MG/KG BB50-500 MG/KG BB 55 TOKSIK EKSTREMTOKSIK EKSTREM 5-50 MG/KG BB5-50 MG/KG BB 66 SUPER TOKSIKSUPER TOKSIK < 5 MG/KG BB< 5 MG/KG BB
  • 4. INDEKS TERAPIINDEKS TERAPI = LD 50 / ED 50= LD 50 / ED 50 MAKINMAKIN BESARBESAR MAKINMAKIN AMANAMAN URUTAN TOKSISITAS DITINJAU DARIURUTAN TOKSISITAS DITINJAU DARI RUTE PEMBERIAN:RUTE PEMBERIAN: IV > INHALASI > IP > SC > IM > INTRAIV > INHALASI > IP > SC > IM > INTRA DERMAL > ORAL > TOPIKALDERMAL > ORAL > TOPIKAL
  • 5. EFEKEFEK TOKSISITASTOKSISITAS OBATOBAT EMESISEMESIS SALISILATSALISILAT KONSTIPASIKONSTIPASI NARKOTIKANARKOTIKA BRADICARDIBRADICARDI NARKOTIKA, SEDATIVENARKOTIKA, SEDATIVE TACHICARDITACHICARDI AMFETAMIN, ATROPIN,AMFETAMIN, ATROPIN, SALISILAT, KOKAINSALISILAT, KOKAIN MULUT KERINGMULUT KERING AMFETAMIN, ATROPIN,AMFETAMIN, ATROPIN, ANTIHISTAMIN,ANTIHISTAMIN, NARKOTIKNARKOTIK ATAKSIAATAKSIA BARBITURAT, FENITOIN,BARBITURAT, FENITOIN, HALUSINOGENHALUSINOGEN KOMA, DEPRESIKOMA, DEPRESI A.HISTAMIN, A.PSIKOTIKA.HISTAMIN, A.PSIKOTIK
  • 6. PENANGANAN KERACUNANPENANGANAN KERACUNAN PENILAIANPENILAIAN  FUNGSI RESPIRASIFUNGSI RESPIRASI  FUNGSI KARDIOVASKULARFUNGSI KARDIOVASKULAR  GEJALA SSPGEJALA SSP  GEJALA LAINGEJALA LAIN  PENENTUAN KERACUANANPENENTUAN KERACUANAN
  • 7. FAKTOR YGFAKTOR YG MEMPENGARUHIMEMPENGARUHI TOKSISITASTOKSISITAS  KOMPOSISIKOMPOSISI  DOSISDOSIS  RUTE PEMBERIANRUTE PEMBERIAN  METABOLISME TOKSIKMETABOLISME TOKSIK  KONDISI KESEHATANKONDISI KESEHATAN  USIA KEMATANGANUSIA KEMATANGAN  KONDISI NUTRISIKONDISI NUTRISI  GENETIKGENETIK  KELAMINKELAMIN  LINGKUNGANLINGKUNGAN
  • 8. FAKTOR YANG MENENTUKANFAKTOR YANG MENENTUKAN TOKSISITASTOKSISITAS LD 50LD 50 EFEK SAMPINGEFEK SAMPING KECEPATAN TIMBULNYA EFEKKECEPATAN TIMBULNYA EFEK
  • 9. CARA PENANGANANCARA PENANGANAN  PENCUCIAN/LAVAGEPENCUCIAN/LAVAGE  EMESISEMESIS  ADSORBENTADSORBENT  KATARTIKKATARTIK  DEMULSENDEMULSEN  DEKONTAMINASI TOPIKALDEKONTAMINASI TOPIKAL  MENINGKATKAN ELIMINASI ZAT TOKSIKMENINGKATKAN ELIMINASI ZAT TOKSIK  ANTIDOTANTIDOT
  • 10. PENCUCIANPENCUCIAN JK RACUN HRS SGR DIKELUATKAN DRJK RACUN HRS SGR DIKELUATKAN DR LAMBUNGLAMBUNG INDIKASIINDIKASI  1010TIDAK SADAR/SETENGAH SADARTIDAK SADAR/SETENGAH SADAR  REFLEKS MENELAN HILANG:REFLEKS MENELAN HILANG: S.IPECAC TIDAK BISAS.IPECAC TIDAK BISA  SANGAT TOKSIK & BANYAKSANGAT TOKSIK & BANYAK
  • 11. KI :ZAT KOROSIFKI :ZAT KOROSIF PASIEN KEJANGPASIEN KEJANG CAIRAN PENCUCIANCAIRAN PENCUCIAN  NaHCO3NaHCO3  Larutan Garam CaLarutan Garam Ca  Larutan As.TanatLarutan As.Tanat  KMNO4KMNO4  NaCl FisiologisNaCl Fisiologis  AirAir
  • 12. EMESISEMESIS JK RACUN MASIH DI SAL CERNAJK RACUN MASIH DI SAL CERNA SIRUP IPECACSIRUP IPECAC APOMORFINAPOMORFIN ALTERNATIF LAINALTERNATIF LAIN LARUTAN SABUNLARUTAN SABUN RANGSANGAN MEKANIKRANGSANGAN MEKANIK KI:KI: OBAT KONVULSANOBAT KONVULSAN TDK SADAR/REFLEKS MENELAN –TDK SADAR/REFLEKS MENELAN – PENYAKIT CARDIOVASKULARPENYAKIT CARDIOVASKULAR EMPISEMAEMPISEMA
  • 13. ADSORBENADSORBEN JK RACUN DPT DIABS D/ ABSORBENJK RACUN DPT DIABS D/ ABSORBEN  KARBON AKTIFKARBON AKTIF  KAOLINKAOLIN  PEKTINPEKTIN  ATALPUGITATALPUGIT  KOLESTIRAMINKOLESTIRAMIN ABSORBSI < :TOLBUTAMID, ZAT TDKABSORBSI < :TOLBUTAMID, ZAT TDK LRT AIRLRT AIR
  • 14. KATARTIK JK DIDUGA ZAT TOKSIK SDH MSK USUS  MgSO4  Mg SITRAT  Na SULFAT  Na FOSFAT  SORBITOL  Sbg pencahar
  • 15. DEMULSEN • ES KRIM • SUSU • PUTIH TELUR  Lapisi muk zat racun yg korosif DEKONTAMINASI TOPIKAL • AIR • SABUN  u/ zat iritan
  • 16. PENINGKATAN ELIMINASIPENINGKATAN ELIMINASI  DIURETIK KUATDIURETIK KUAT  Yg dpt dikeluarkan diuretik kuatYg dpt dikeluarkan diuretik kuat amfetamin,penicillin,salisilat,sulfonamidaamfetamin,penicillin,salisilat,sulfonamida KI : ACETAMINOPHEN,FENOTIAZINKI : ACETAMINOPHEN,FENOTIAZIN A.DEPRESSAN TRISIKLIK,barbiturat krjA.DEPRESSAN TRISIKLIK,barbiturat krj pendekpendek **DIALISISDIALISIS *PENGASAMAN/PEMBASAAN URIN*PENGASAMAN/PEMBASAAN URIN
  • 17. ANTIDOTANTIDOT  KIMIAKIMIA  RESEPTORRESEPTOR  DISPOSIONALDISPOSIONAL  FUNGSIONAL/FISIOLOGISFUNGSIONAL/FISIOLOGIS
  • 18.  ANTIDOTANTIDOT ATROPIN----------------ATROPIN---------------- DIAZEPAM--------------DIAZEPAM-------------- DEKTROSE-------------DEKTROSE------------- ADRENALIN------------ADRENALIN------------ DOPAMIN---------------DOPAMIN--------------- NALOKSON-------------NALOKSON------------- NITROPRUSID---------NITROPRUSID--------- -- PROTAMIN SULFAT--PROTAMIN SULFAT-- VIT K-----------------VIT K----------------- ASETILASETIL SISTEIN-----SISTEIN-----  RACUN/GEJALARACUN/GEJALA KOLINESTERASE INHKOLINESTERASE INH STIMULAN SSPSTIMULAN SSP HIPOGLIKEMIKHIPOGLIKEMIK ANAPHYLAKSIISANAPHYLAKSIIS HIPOTENSIHIPOTENSI OPIOIDOPIOID HIPERTENSIHIPERTENSI HEPARINHEPARIN ANTIKOAGULANORALANTIKOAGULANORAL ACHETAMINOPHENACHETAMINOPHEN
  • 19. KERACUNAN ACETAMINOPHEN  MK: METABOLIT REAKTIF IK SEL NECROSIS HB MET HB(TDK IK O2) O2 PAR HB (ENZ MET HB REDUKTASE) KOFAKTOR : GLUTATION
  • 20.
  • 21. • AnjAnj  nekrosis hepatiknekrosis hepatik • KucKuc Met HemoglobinemiaMet Hemoglobinemia DOSIS TOKSIKDOSIS TOKSIK ANJ : 150 MG/KGANJ : 150 MG/KG KUC : 50 MG/KGKUC : 50 MG/KG (DOSIS AN: 80 MG(DOSIS AN: 80 MG REG: 325-500MG)REG: 325-500MG)
  • 22. GEJALAGEJALA ► ANJ: - DEPRESIANJ: - DEPRESI - MUNTAH- MUNTAH - SKT ABD- SKT ABD - URIN,SERUM: GELAP- URIN,SERUM: GELAP - MATI ( 2-5 HR)- MATI ( 2-5 HR) ► KUCKUC - ANOREKSI,SALIVASI,VOMIT- ANOREKSI,SALIVASI,VOMIT - DEPRESI- DEPRESI - METHBNEMIA, HEMOGLOBINURIA- METHBNEMIA, HEMOGLOBINURIA - MEMBRAN CYANOTIK- MEMBRAN CYANOTIK - URIN, DARAH GELAP- URIN, DARAH GELAP - WAJAH EDEMA- WAJAH EDEMA - MATI 18-36 J- MATI 18-36 J
  • 23.  PROGNOSIS: JELEKPROGNOSIS: JELEK  TREATMENTTREATMENT - <4J: EMESIS, GASTRIC LAVAGE,- <4J: EMESIS, GASTRIC LAVAGE, ACTIVATED CHARCOALACTIVATED CHARCOAL KUC: YOHIMBINKUC: YOHIMBIN ANJ: APOMORPHINANJ: APOMORPHIN -GROUP SULFHYDRYL:N--GROUP SULFHYDRYL:N- ACETILCYSTEINE 140 MG/KGACETILCYSTEINE 140 MG/KG - VIT C- VIT C - SUPPORTIVE THERAPY- SUPPORTIVE THERAPY -INFUSE : DECTROSE 2,5%-INFUSE : DECTROSE 2,5% -OXYGEN:-OXYGEN: -TRANSFUSI DRH-TRANSFUSI DRH
  • 24. ASPIRIN TOXICOSISASPIRIN TOXICOSIS  KUC > SERING DRPD ANJKUC > SERING DRPD ANJ C/ KUC:DEF/AKTC/ KUC:DEF/AKT GLUCORONYLGLUCORONYL TRANSFERASETRANSFERASE << (GT : DETOX & EKS ASPIRIN)(GT : DETOX & EKS ASPIRIN) EFEK TOKSIK:EFEK TOKSIK: - TEKAN SUTUL- TEKAN SUTUL - HAMB AGREGASI TROMBOSIT- HAMB AGREGASI TROMBOSIT - METABOLIC ACIDOSIS- METABOLIC ACIDOSIS - RENAL DISEASE- RENAL DISEASE - GASTRIC ULCERASI- GASTRIC ULCERASI
  • 25. DOSIS TOXIC:DOSIS TOXIC: - ANJ : 30 MG /KG/HR- ANJ : 30 MG /KG/HR - KUC : 25 MG/KG/HR- KUC : 25 MG/KG/HR (ANAK : 81 MG(ANAK : 81 MG REG : 325- 500 MG)REG : 325- 500 MG) GJL:-AKUT:GJL:-AKUT: DEPRESI, ANOREKSI,DEPRESI, ANOREKSI, HIPERPIREXIA, VOMIT,HIPERPIREXIA, VOMIT, ATAKSIA,ATAKSIA, COMA, MATICOMA, MATI
  • 26.  KRONIK:KRONIK: GASTRIK ULCER, PERFORASI,GASTRIK ULCER, PERFORASI, HEPATOTIKSIK, SUPRESI SUTULHEPATOTIKSIK, SUPRESI SUTUL TREATMENTTREATMENT 1. 6-12 J : EMETIK,GASTREK1. 6-12 J : EMETIK,GASTREK LAVAGE,LAVAGE, ACT CHARCOAL, SALINEACT CHARCOAL, SALINE CATARTIKCATARTIK 2. DIURESIS : DIURETIK KUAT2. DIURESIS : DIURETIK KUAT
  • 27. IBUPROFENIBUPROFEN  NSAID YG TDK DIREKOMENDASI UTKNSAID YG TDK DIREKOMENDASI UTK PETSPETS  IT SEMPITIT SEMPIT  TOKSISITAS:TOKSISITAS: - 150 mg/kg- 150 mg/kg vomit, gastric ulcervomit, gastric ulcer - 300 mg/kg- 300 mg/kg  ggl ginjalggl ginjal  PROG : JLKPROG : JLK  TREAT: 1. EMETIK, GASTRIK L, ATREAT: 1. EMETIK, GASTRIK L, A CHARCOALCHARCOAL 2. support: infus, diuresis2. support: infus, diuresis 3. simpt: sucralfat, ranitidin,3. simpt: sucralfat, ranitidin, misotrostolmisotrostol g.ulcerg.ulcer
  • 28. ANTICOAGULANT  MK : -INH ENZ PD SINTESIS VIT K - INH FACT COAG PROD VIT K  TOXIC DOSE * ANJ : 5-300 MG/KG (1-5 MG/KG/HR 5-15 HR) * KUC: 5-30 MG/KG (1 MG/KG/HR 5 HR)  GJL:- DEPRESI,LEMAH - HEMATEMESIS,HEMATURIA,HEMORRHAGE - MATI HEMORRHAGE D/PLEURAL CAVITY  DX:-HISTORY - SCREENING KOAG: BLEEDING TIME, COAG TIME - ANALISIS A.COAG KIMIA
  • 29. • TREATMENT 1. INDUKSI EMESIS, GASTRIC LAVAGE, ACTIVED CHATCOAL, CATHARTIC 2. ANTIDOTE: VIT K 3. TREAT CLINICAL SIGN - INTRAPULMONARY HEMORRHAGE: TRANSFUSI PLASMA, O2, TDK BOLEH DIBERI FUROSEMIDE INH FS PLATELET - HIPOVOLEMIC SHOCK: INFUSE,TRANSF DRH, KORTICOSTEROID,
  • 30. A.HISTAMIN&DECONGESTAN  DX: SEJARAH PSEUDOEPHEDRIN, (PHENYLPROPANOLAMINE)/PPA,DIPHENH YDRAMINE, CHLORPHENIRAMINE  GJL:- DEPRESI, GG RESP, - HIPEREXCITABILITY - TREMOR, SEIZURES, HIPERACTIVITY - VOMIT, MIDRIASIS, HIPERTERMIA - DISORIENTASI - BRADICARD/TACHICARD
  • 31.  PROG: BAIK  TREAT: 1. < 1 J INTAKEEMESIS 2. ACTIVATED CHARCOAL 3. SUPPORTIVE: INFUSE, O2 4. OBAT SEDATIVE HIPERACVTIVE (DIAZEPAM,PHENOBARBITAL) 5. PROPANOLOLTACHYCARDI 6. ATROPINE BRADYCARD